Tinzaparin and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Tinzaparin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both apixaban (Eliquis) and tinzaparin are blood thinners. They work in different ways, but they both make your blood clot less easily. Taking them together adds their effects up, so your risk of bleeding goes up, and in some cases that bleeding can be serious.
Watch for warning signs like unusual bruising, bleeding that will not stop, pink or red urine, black or bloody stools, coughing or vomiting blood, or a bad headache. If any of these happen, get help right away or go to the emergency room. The good news is your care team knows how to handle this safely by choosing the right doses and keeping a close eye on you.
Additive anticoagulation. Apixaban (direct factor Xa inhibitor) plus tinzaparin (LMWH, indirect anti-Xa activity) produces overlapping anticoagulant effects and increased bleeding risk. Neither is a prodrug; this is a pharmacodynamic, not metabolic, interaction. Studies with apixaban plus enoxaparin showed a 50 to 60 percent rise in anti-Xa activity.
- Direction: increased anticoagulant effect and bleeding risk.
- Evidence: probable; severity major.
- Management: avoid overlap unless clinically necessary; if active pathological bleeding occurs, discontinue apixaban. Effect persists at least 24 hours after last dose. A specific reversal agent is available; PCC, aPCC, or recombinant factor VIIa may be considered. Note PT/INR/aPTT and anti-Xa are not useful for monitoring reversal when PCCs are used.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Using apixaban, a factor Xa inhibitor, together with another anticoagulant raises the likelihood of bleeding. Pharmacodynamic interaction studies involving apixaban demonstrated a 50% to 60% rise in anti-factor Xa activity when apixaban was given alongside enoxaparin. Should active pathological bleeding develop, apixaban should be stopped. There is an agent available that reverses apixaban's anti-factor Xa activity. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Patients should be counseled about the signs and symptoms of blood loss and instructed to report these promptly or proceed to an emergency room. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, it is neither useful nor recommended to assess apixaban's anticoagulant effect through a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity. Absorption of apixaban is diminished by activated oral charcoal, which consequently reduces apixaban exposure1.
Why it happens (mechanism)
Additive anticoagulation
How to manage this interaction
Both drugs thin the blood, so using them together raises bleeding risk. Do not start, stop, or change either one on your own. Instead:
- Keep taking both exactly as prescribed unless your care team tells you otherwise.
- Your team may adjust and individualize your doses and monitor you more closely while you are on both.
- Learn the signs of bleeding (unusual bruising, blood in urine or stool, coughing or vomiting blood, severe headache) and report them immediately or go to the emergency room.
- If serious bleeding happens, your team can stop the apixaban and use a reversal agent; note its effect can last at least 24 hours after the last dose.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In investigations of pharmacodynamic drug interactions involving apixaban, a 50% to 60% rise in anti-factor Xa activity was noted when apixaban was given together with enoxaparin 1.
Common questions
Can I take Tinzaparin and Apixaban together?
Apixaban and tinzaparin are both blood thinners, and using them together adds up their effects and raises the risk of serious bleeding. Take both only as prescribed, watch for bleeding, and seek emergency care right away if it occurs. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Tinzaparin and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Tinzaparin and Apixaban interaction managed?
Both drugs thin the blood, so using them together raises bleeding risk. Do not start, stop, or change either one on your own. Instead: Keep taking both exactly as prescribed unless your care team tells you otherwise. Your team may adjust and individualize your doses and monitor you more closely while you are on both. Learn the signs of bleeding (unusual bruising, blood in urine or stool, coughing… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Tinzaparin or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Apixaban
Keep reading about Tinzaparin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist